PharmaTher Archives

Psychedelics News

PharmaTher

Industry

27 Sep 2023

FDA Accepts PharmaTher’s New Drug Application for KETARX™ (Ketamine)

The FDA has accepted the company’s Abbreviated New Drug Application for KETARX™ (racemic ketamine). The goal date for this priority original ANDA of April 29, 2024....

By Microdose NewsDesk

Breaking News

6 Sep 2023

PharmaTher Submits New Drug Application to the FDA

Will PharmaTher be the next company to get a psychedelic medicine to market?...

By Jason Najum

Industry

19 Jul 2023

PharmaTher Announces Positive Research Results for DMT and Investment into Sairiyo Therapeutics

PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics...

By Microdose NewsDesk

Industry

27 Jun 2023

PharmaTher Initiates Filing of Abbreviated New Drug Application to the FDA

PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

29 Mar 2023

PharmaTher Announces Positive FDA Meeting; Path Towards Phase 3 Trial

PharmaTher continues to move its niche ketamine programs through the FDA process....

By Microdose NewsDesk

Industry

2 Feb 2023

FDA Grants Pharmather Orphan Drug Designation for KETARX (Ketamine)

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome...

By Microdose NewsDesk

Industry

15 Dec 2022

PharmaTher Receives FDA Orphan Drug Designation for Ketamine

The U.S. Food and Drug Administration (FDA) has granted PharmaTher orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation...

By Microdose NewsDesk

Industry

3 Nov 2022

PharmaTher Enters into Agreement to Commercialize Ketamine for Rett Syndrome

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome...

By Microdose NewsDesk

Industry

5 Oct 2022

PharmaTher Granted U.S. Patent Covering Ketamine for Parkinson’s

PharmaTher Holdings Announces Grant of U....

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result